Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 3: Pharmacoeconomics in Oncology: Direct and Indirect Costs
Submit an article Journal homepage
455
Views
5
CrossRef citations to date
0
Altmetric
Original research

Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer

Li-Jen Chenga Agency for Care Effectiveness, Ministry of Health, SingaporeORCID Iconhttps://orcid.org/0000-0002-8371-8864View further author information
ORCID Icon,
Grace Wonga Agency for Care Effectiveness, Ministry of Health, SingaporeView further author information
,
Wen-Yee Chayb Division of Medical Oncology, National Cancer Centre Singapore, Singapore;c Duke-NUS Medical School, National University of Singapore, SingaporeView further author information
,
Joanne Ngeowb Division of Medical Oncology, National Cancer Centre Singapore, Singapore;c Duke-NUS Medical School, National University of Singapore, Singapore;d Lee Kong Chian School of Medicine, Nanyang Technological University, SingaporeView further author information
,
Yongqiang Tana Agency for Care Effectiveness, Ministry of Health, SingaporeView further author information
,
Swee Sung Soona Agency for Care Effectiveness, Ministry of Health, SingaporeView further author information
,
Mohamed Ismail Abdul Aziza Agency for Care Effectiveness, Ministry of Health, SingaporeORCID Iconhttps://orcid.org/0000-0002-6511-1639View further author information
ORCID Icon,
Fiona Pearcea Agency for Care Effectiveness, Ministry of Health, SingaporeView further author information
&
Kwong Nga Agency for Care Effectiveness, Ministry of Health, SingaporeCorrespondence[email protected]
View further author information
 show all
Pages 441-448 | Received 07 Jan 2021, Accepted 10 Feb 2021, Published online: 08 Mar 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

John Hang Leung, Hui-Chu Lang, Shyh-Yau Wang, Hsueh Fang Lo & Agnes LF Chan. (2022) Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer. Expert Review of Pharmacoeconomics & Outcomes Research 22:3, pages 489-496.
Read now

Articles from other publishers (4)

Jing Nie, Huina Wu, Lei Sun, Yanjiao Ding, Yepeng Luan & Jiyong Wu. (2023) Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China. Frontiers in Pharmacology 13.
Crossref
Yamin Shu, Yanxin Liu, Xucheng He, Yufeng Ding & Qilin Zhang. (2022) Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china. Frontiers in Pharmacology 13.
Crossref
Rachel Su-En See-Toh, Xin Yi Wong, Kush Shiv Kishore Herkshin Mahboobani, Swee Sung Soon, Benjamin Kearns, Katy Cooper, Kay Woon Ho, Ivandito Kuntjoro & Kwong Ng. (2022) Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore. BMC Health Services Research 22:1.
Crossref
Vivien Kin Yi Chan, Runqing Yang, Ian Chi Kei Wong & Xue Li. (2022) Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review. Frontiers in Pharmacology 13.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.